Loading...
OTCM
NNBP
Market cap0USD
Mar 20, Last price  
0.00USD
Name

Nanobac Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:NNBP chart
P/E
0.00
P/S
0.00
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
18k
-92.17%
3,700,0006,200,0008,876,6529,942,0508,774,4196,844,36111,555482,815358,361656,802225,08617,621
Net income
-7m
L+32.23%
100,000-800,000-1,241,661-1,910,131-2,679,393-2,739,072-1,475,299-3,699,491-7,874,778-3,687,337-4,973,353-6,576,111
CFO
-911k
L-64.76%
700,000-300,000464,462426,142528,004-72,688-1,069,670-2,155,322-3,395,744-2,365,310-2,584,882-910,886

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nanobac Pharmaceuticals, Incorporated is dedicated to advancing human health through the creation and refinement of products and services designed for the identification and management of calcifying nanoparticles (CNPs). The company's offerings include the production and sale of in vitro diagnostic (IVD) kits, which encompass assays, antibodies, and reagents specifically developed for detecting CNPs. Notably, their diagnostic assays include NANO-CAPTURE and NANO-SERO. Furthermore, Nanobac engages in research and clinical studies focused on various urological diseases—such as chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases—as well as cardiovascular ailments. Established in 1994 and headquartered in Tampa, Florida, the company operated as HealthCentrics Inc. until its name change to Nanobac Pharmaceuticals, Incorporated in December 2002.
URL
IPO date
Jun 21, 2001
Employees
Domiciled in
US
Incorporated in
US

Valuation

No data to show